*001256314
*00520250613115248.0
*007ta
*008110930s2003    no            000 u eng d
*00901307cam a2200277 c 4500
*019  $bl
*020  $a8249102681$qh.
*035  $a(EXLNZ-47BIBSYS_NETWORK)990312892404702201
*035  $a(NO-LaBS)13926030(bibid)
*035  $a(NO-TrBIB)03128924x
*035  $a03128924x-47bibsys_network
*040  $aNO-TrBIB$bnob$ekatreg
*1001 $aBjorvatn, Afsaneh$0(NO-TrBIB)90805189$_29683500
*24510$aCost-effectiveness of Fondaparinux vs Enoxaparin as venous thromboembolism prophylaxis in Norway$cby Afsane Bjorvatn, Frode Kristiansen
*260  $aBergen$bInstitute for Research in Economics and Business Administration$c2003
*300  $a58 s.$bill.
*4901 $aSNF-rapport$vnr 13/03
*500  $aProsjektnr : 2725
*500  $aSNF-prosjekt: Cost-effectiveness of Fondaparinux (Arixtra)- a Norwegian analysis
*533  $aElektronisk reproduksjon$b[Norge]$cNasjonalbiblioteket Digital$d2016-07-19
*7001 $aKristiansen, Frode$d1959$0(NO-TrBIB)10000249$_20592700
*7760 $tCost-effectiveness of Fondaparinux vs Enoxaparin as venous thromboembolism prophylaxis in Norway$w990418545864702201
*830 0$aSNF-rapport (trykt utg.)$x0803-4036$vnr 13/03$w999106744344702201$_11472200
*85641$3Fulltekst$uhttps://urn.nb.no/URN:NBN:no-nb_digibok_2016071908176$yNettbiblioteket$zDigital representasjon
*901  $a80
*999  $aoai:nb.bibsys.no:990312892404702202$b2021-11-14T20:04:39Z$z990312892404702202
^